Immune Design Corp. (IDC) is a clinical-stage immunotherapy company that focuses on next-generation in vivo methods to empower the body's immune system in fighting diseases. With a strong emphasis on oncology, IDC is developing tumor-specific cytotoxic T cells to combat cancer. Their groundbreaking discoveries, CMB305 and G100, offer immuno-oncology approaches that aim to overcome the limitations of current cancer therapies. Through dedicated research and a commitment to excellence, IDC strives to alleviate human suffering by creating safe and effective immune-based products for the pharmaceutical industry.